GlassScriptPhysician profile
Gina D Duggar
NPI 1639174600
$4,495.82
in general payments reported to CMS, 2019-2025
40 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.80 · 2022: $952 · 2023: $1,128 · 2024: $1,354 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931 · Education: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.91 |
| Education | $580.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,014.69 | 2021-2025 | |
| Seagen INC. | $786.44 | 2022-2024 | Adcetris, Tukysa, Padcev |
| Astellas Pharma US INC | $272.85 | 2022-2024 | Padcev |
| Lilly USA, LLC | $164.54 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $156.99 | 2023-2025 | |
| Eisai INC. | $155.65 | 2022-2025 | |
| Janssen Biotech, INC. | $153.05 | 2023-2025 | Erleada, Darzalex, Tecvayli |
| Incyte Corporation | $140.27 | 2023-2024 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $136.76 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $130.92 | 2023-2025 | Keytruda |
| Daiichi Sankyo INC. | $122.27 | 2023-2025 | Enhertu, Datroway |
| Geron Corporation | $100.47 | 2024-2025 | Rytelo |
| Amgen INC. | $96.64 | 2022-2023 | Lumakras |
| Genentech USA, INC. | $87.93 | 2023-2024 | Alecensa, Tecentriq, Rozlytrek |
| E.R. Squibb & Sons, L.L.C. | $86.12 | 2022-2025 | Opdualag, Opdivo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.52 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $79.67 | 2024-2025 | |
| Sobi, INC | $67.07 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $60.61 | 2023-2024 | Xpovio |
| Celgene Corporation | $53.41 | 2022 | |
| Exelixis INC. | $45.81 | 2023-2025 | Cabometyx |
| Puma Biotechnology, INC. | $44.33 | 2024-2025 | |
| Gilead Sciences, INC. | $43.42 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $38.95 | 2024-2025 | Ultomiris |
| Caris Mpi, INC. | $35.48 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $31.50 | 2023-2024 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $29.94 | 2023 | Iclusig |
| Array Biopharma INC | $29.24 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Deciphera Pharmaceuticals INC. | $25.24 | 2024 | Qinlock, Tgct |
| Astrazeneca Pharmaceuticals LP | $25.02 | 2024 | Lynparza |
| Beigene USA, INC. | $22.53 | 2024 | Brukinsa |
| Beone Medicines USA, INC. | $21.70 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $21.02 | 2022 | |
| Genzyme Corporation | $20.96 | 2024 | |
| Glaxosmithkline, LLC. | $20.86 | 2024 | Ojjaara |
| G1 Therapeutics, INC. | $20.57 | 2023 | Cosela |
| Alnylam Pharmaceuticals INC. | $19.83 | 2023 | Onpattro |
| Mirati Therapeutics, INC. | $19.67 | 2023 | Krazati |
| Ipsen Biopharmaceuticals, INC | $17.60 | 2024 | Onivyde |
| Stemline Therapeutics INC. | $14.28 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Duggar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.